stats i get wrong (obs) Flashcards
PET: risk of any HTN in future pregnancy
20%
PET: risk of PET if birth 28-34 weeks
33% (1 in 3)
PET: risk of PET if birth 34-37 weeks
23% (1 in 4)
PET: risk of gestational HTN
6-12%
PIH: risk of any HTN in future pregnancy
22% (1 in 5)
PIH: risk of PET
7% (1 in 14)
PIH: risk of PIH again
11-15%
PET: risk of chronic HTN
2% (1 in 50)
PIH: risk of chronic HTN
3%
statistic:
Success planned VBAC overall
72-75%
RCOG. Green-top Guideline No.45: Birth after previous caesarean birth. October 2015.
Statistic:
Success VBAC with previous VBAC
85-90%
Previous NVD (especially VBAC), is the single best predictor of success
RCOG. Green-top Guideline No.45: Birth after previous caesarean birth. October 2015.
Statistic:
Success VBAC if previous C/S for fetal malpresentation
84%
RCOG. Green-top Guideline No.45: Birth after previous caesarean birth. October 2015.
Statistic:
Success VBAC if previous C/S for fetal distress
73%
RCOG. Green-top Guideline No.45: Birth after previous caesarean birth. October 2015.
Statistic:
Success VBAC if previous C/S for labour dystocia
64%
Successful VBAC appears to be more likely if dystocia at 8cm or more
RCOG. Green-top Guideline No.45: Birth after previous caesarean birth. October 2015.
Statistic:
Success VBAC if previous C/S for failed instrumental
61%
RF for failure: OP and prolonged 2nd stage as indication for instrument
RCOG. Green-top Guideline No.45: Birth after previous caesarean birth. October 2015.
Incidence accreta with previa and previous C/S x1
11%
Incidence Previa without C/S
1/400
Incidence previa with Previous C/S x1
1/160 (0.60%)
Incidence previa with Previous C/S x2
1/60 (1.6%)
Incidence previa with Previous C/S x3
1/30 (3.3%)
Incidence previa with Previous C/S x4
1/10 (10%)
Incidence accreta with Previa and previous C/S x2
40%
Incidence accreta with previa and previous C/S x3
61%
Incidence accreta with Previa and previous C/S x4
67%
Risk of further laparotomy after C/S: normal vs. previa
5/1000
vs
75/1000
Risk of VTE in C/S : normal vs. previa
4-16/10 000
vs
3/100
Risk bladder injury in C/S: normal vs. previa
1/1000
vs
6/100
Risk future previa after c/s for previa
23/1000
4-8/1000 risk of future placental abnormality in normal ELCS
Risk of hysterectomy in c/s: normal vs. previa
7-8/1000
vs
11/100 (27/100 if previous c/s)
Risk of ureteric injury in C/S (normal)
3/10 000
Risk of infxn in C/S (normal)
6%
Upper medial thigh sensory loss
Weakness leg adduction
Obturator nerve
Foot and anterolateral leg sensory loss
Foot drop
Loss of ant compartment extensors
Common peroneal nerve
Lateral thigh sensory loss
Lateral femoral cutaneous nerve
Anterior thigh and knee sensory loss
Loss of knee jerk reflex
Quadriceps weakness
Femoral nerve
face presentation
submentobregmatic 9.5cm
brow presentation
mentovertical 13.5-14cm
deflexed OP
occipitofrontal 11.4cm
vertex presentation
suboccipitobregmatic 9.5cm
fetal loss in simple appendicitis
1.5%
fetal loss in appendicitis with peritonitis
6%
fetal loss with perforated appendix
36%
rate of SB 25-29yo
4.6/1000 maternities (1/217)
rate of SB 30-34yo
4.7/1000 maternities (1/213)
rate of SB 35-39yo
5.5/1000 maternities (1/182)
rate of SB >40yo
7.6/1000 maternities (1/132)
rate of NND 25-29yo
2.9/1000 live births (1/345)
rate of NND 30-34yo
2.6/1000 live births (1/385)
rate of NND 35-39yo
2.9/1000 live births (1/345)
rate of NND >40yo
3.8/1000 live births (1/263)
RR of NND for women >40 compared to 25-29yo
1.3x
recurrence of OASIS
7.2%
untreated antiphospholipid syndrome - how many will progress to PIH/PET
30-50%
peurperal genital hematoma incidence
1/700
1/1000 requiring surgical intervention
% OASIS with fecal incontinence at 12 months
30%
C/S for breech if:
- hyperextended neck on USS
- LGA>3.8kg
- SGA<10%
- footling
- fetal compromise
incidence of postpartum psychosis
1-2/1000
rubella - spontaneous miscarriage in 1st trimester
20%
congenital rubella if in <11/40
90%
congenital rubella if in 11-16/40
20%
incidence of CMV
0.2-2.2% live births
risk of congenital CMV if primary infections
30-40%
primary infection only 1% of pregnancies
risk of congenital CMV if recurrent infection
1-2%
congenital CMV - what % will have signs at birth
10-15%
congenital CMV - what % will develop symptoms later on
10-15%
congenital CMV - what % will have SNHL
6%
severe congenital CMV - % neuro impairment
80%
severe congenital CMV - % deafness
50%
severe congenital CMV - % defective teeth
40%
moderate/mild congenital CMV - most common symptoms
hearing loss 20%
CMV - when to investigate
CMV PCR via amniocentesis 6-8 weeks after infection, after 20/40
chlamydia in pregnancy - what % neonates will develop ophthalmia
50%
chlamydia in pregnancy - what % of those delivering vaginal will develop puerperal sepsis/infection
34%
chlamydia in pregnancy - when to do test of cure
5-6 weeks
management of acute MI in pregnancy
- avoid nifedipine
- delay IOL 2-3 weeks if possible
- delivery in high risk unit
most common cause of cardiac death if no risk factors
dissection, 14%
heart valve associated with rheumatic heart disease
mitral stenosis
eisenmeiger syndrome - risk of maternal mortality
20-40%; advise against pregnancy
incidence of asthma in pregnancy
4-12%
SB at term in mat age <35
1/1000
SB at term in mat age >40
2/1000
postmortem after SB, can provide info regarding cause of death in ___%
46% autopsy alone, or 51% if combined with other tests
postmortem after SB can provide info regarding risk of recurrence in ___%
40%
SB - what % will labour spontaneously
85% within 3 weeks;
- 90% achieve NVD within 24h of IOL
risk of death from hemorrhage in jehovahs witness
44x increased
how much FFP to transfuse
12-15ml/kg (4 units) for every 6 units RBC; aim PT/APTT <1.5x
how much cryo to transfuse
2x5 unit pools, if fibrinogen <1.0, for target >1.5
when to start platelet transfusion in hemorrhage
when PLT<75, but target >50
if Rh+ PLTs given to Rh- woman?
give 250units anti-D, will be good enough to cover 6 pools
if Rh+ Cryo or FFP given to Rh- woman?
do nothing
when to use cell salvage
if EBL expected to induce anemia, or >20% of total blood volume
adrenaline dose for anaphylaxis
1:1000
500mcg, 0.5ml IM
incidence of MOH/collapse
6/1000
incidence of AFE
1.7/100 000
survival of AFE
81%
incidence of anaphylaxis
1-3.5/100 000
mortality of anaphylaxis
1%
criteria for diagnosis of anaphylaxis
- sudden onset and rapid progression
- life threatening airway and circulation problems
- skin+/- mucosal changes
when to measure mast cell tryptase in anaphylaxis
- at start of CPR
- at 1-2h
- at 24h
adjunctive treatment/doses for anaphylaxis
chlorphenamine 10mg,
hydrocortisone 200mg IM or IV
cardiac arrest in pregnancy incidence and fatality
1/36 000
- 42% fatality
aortocaval compression decreases cardiac output by how much
30-40%
at term, uterus receives how much of cardiac output
10%
above what BMI is GDM screening necessary
> 30
above what BMI are serial growth scans necessary
> 35
above what BMI is anaesthetic review required
> 40
above what BMI IV access required intrapartum
> 40
bariatric surgery increases what risks
FETAL:
- SGA, PTL, NICU
MATERNAL:
- anemia, low B12, ADEK deficiency
thromboprophylaxis for obesity
- antenatal: BMI>30 scores 1
- postnatal: all women with BMI>40 should get 10/7 LMWH